The U.S. Food and Drug Administration restored GSK’s antibody‑drug conjugate Blenrep to the U.S. market with a narrowed approval for third‑line treatment of multiple myeloma. The decision follows earlier regulatory setbacks after a failed confirmatory trial and comes with a more limited label than recent European approvals. GSK framed the approval as a calibrated return to market and expects to reintroduce the medicine in a restricted indication while continuing development and lifecycle work.